Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial

Selumetinib in Children with Inoperable Plexiform Neurofibromas

(2020) Andrea M. Gross et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1

(2020) Amy E. Armstrong et al.   PEDIATRIC BLOOD & CANCER

Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1

(2018) Andrea M Gross et al.   NEURO-ONCOLOGY

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurofibromatosis Clinical Trial Consortium

(2017) Roger J. Packer et al.   JOURNAL OF CHILD NEUROLOGY

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

(2017) Maria E. Cabanillas et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

(2017) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity

(2017) Kavitha Nutakki et al.   JOURNAL OF NEURO-ONCOLOGY

Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies

(2017) Marie Schoumacher et al.   Current Oncology Reports

Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults

(2016) Linh Nguyen et al.   ANTI-CANCER DRUGS

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers

(2016) Rebecca Lock et al.   JOURNAL OF CLINICAL INVESTIGATION

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial

(2016) Raya Leibowitz-Amit et al.   Journal of Translational Medicine

Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas

(2016) Eva Dombi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

(2016) Sara M. Tolaney et al.   ONCOLOGIST

Cabozantinib Approved for Renal Cell Carcinoma

(2016)   Cancer Discovery

Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1

(2015) Edwin Jousma et al.   PEDIATRIC BLOOD & CANCER

Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas

(2015) Michael J. Ferguson et al.   PEDIATRIC BLOOD & CANCER

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study

(2014) B. Weiss et al.   NEURO-ONCOLOGY

Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma

(2014) Sahzene Yavuz et al.   THYROID

Optimizing biologically targeted clinical trials for neurofibromatosis

(2013) David H Gutmann et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

(2013) David Viola et al.   Future Oncology

Achieving consensus for clinical trials: The REiNS International Collaboration

(2013) S. R. Plotkin et al.   NEUROLOGY

Recommendations for imaging tumor response in neurofibromatosis clinical trials

(2013) E. Dombi et al.   NEUROLOGY

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

(2012) Walter J. Jessen et al.   JOURNAL OF CLINICAL INVESTIGATION

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial

(2012) Kent A Robertson et al.   LANCET ONCOLOGY

Pathogenesis of Plexiform Neurofibroma: Tumor-Stromal/Hematopoietic Interactions in Tumor Progression

(2011) Karl Staser et al.   Annual Review of Pathology-Mechanisms of Disease

Polychromatic flow cytometry identifies novel subsets of circulating cells with angiogenic potential in pediatric solid tumors

(2011) Kamnesh R. Pradhan et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

(2011) Jianqiang Wu et al.   PEDIATRIC BLOOD & CANCER

Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow

(2008) Feng-Chun Yang et al.   CELL

Clinical Experience With Radiation Therapy in the Management of Neurofibromatosis-Associated Central Nervous System Tumors

(2008) Stacy Wentworth et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1

(2008) Victor-F. Mautner et al.   NEURO-ONCOLOGY